Pushing Hard On PD-1, Merck Signs Trio Of Combo Development Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s oncology build-up is continuing, even as it tightens focus and squeezes spending in other parts of its business as part of an ongoing “reshaping” that CFO Peter Kellogg said will help to maximize “core in-line assets and key pipeline programs” that are critical for growth.
You may also be interested in...
Dr. Reddy’s Chairman GV Prasad On Innovation, Biosimilars And Global Challenges: An Interview With PharmAsia News
GV Prasad, Chairman of the $2.13 billion Indian drug firm Dr. Reddy's Laboratories Ltd. is preparing to take his company from predominantly generics to super generics and untapped innovative niche products. His pet project is lower risk innovation via reverse translation by solving problems with existing molecules.
Emerging Markets Earnings Roundup: Merck, AstraZeneca (Part 6)
Merck comes up short on goal to reach 25% of total sales from emerging markets and sees headwinds on diabetes. AstraZeneca is full-steam ahead on China with headcount expansion in 2013 paving the way for gains in 2014, CEO Pascal Soriot says.
Two Approaches To PD-1 Blocker Pediatric Studies Could Help Clarify Biomarker’s Role
Merck plans to enrich its Phase II study for MK-3475 with patients whose tumors express PD-L1; Bristol would take all comers in its Phase I/II trial of nivolumab.